

AMENDMENTS TO THE CLAIMS

1-43. (Previously Cancelled)

44. (Currently Amended) A method for providing an artificial chemotactic factor gradient *in vivo* comprising administering a composition comprising one or more chemotactic factor(s), wherein transient entrapment of antigen presenting cells is achieved.

45. (Previously Amended) The method of claim 44 wherein the composition further comprises a device.

46. (Previously Amended) The method of claim 44 wherein the chemotactic factor is a chemokine.

47. (Previously Amended) The method of claim 46 wherein the composition further comprises a device.

48. (Currently Amended) The method of claim 45 wherein the device is comprises ethylene-vinyl-acetate.

49-64. (Previously Cancelled)

65. (Previously Amended) The method of claim 44, 45 or 133 wherein the chemotactic factor is selected from the group consisting of chemokines, nucleotides and neuropeptides.

66. (Previously Amended) The method of claim 46, 47, 48 or 133 wherein the chemokine is selected from the group consisting of MIP-1 $\alpha$ , RANTES, MCP-3, MIP-5, MCPs, TARC, MDC, MIP-3 $\alpha$ , IL-8, SDF-1, MIP-3 $\beta$  and SLC.

67. (Withdrawn)

68. (Withdrawn)

69. (Currently Amended) The method of claim 66 wherein the chemokine is MIP-3 $\beta$ .

70-120. (Previously Cancelled)

121. (Previously Amended) The method of claim 44 and 45 wherein the composition is administered subcutaneously.

122-132. (Previously Cancelled)

133. (Previously Added) The method of claim 47 wherein the device is ethylene-vinyl-acetate.